Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Advance
  • Published:

Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?

Abstract

Randomized, controlled trials and subsequent observational studies in routine clinical practice have shown that intravenous recombinant tissue plasminogen activator is safe and effective when used in selected patients within 3h of the onset of acute ischemic stroke. Results of the ECASS III (European Cooperative Acute Stroke Study III) trial have now confirmed the finding of a previous meta-analysis of data from individual patients from smaller trials, which showed that the time-window for benefit actually extends to 4.5h. However, the absolute benefit of treatment falls substantially with time after the onset of ischemic stroke and clinicians should, therefore, still aim to treat patients with intravenous recombinant tissue plasminogen activator within 90 min of stroke onset, if at all possible. Ongoing trials aim to determine whether eligibility for thrombolysis can be extended in other ways, such as to patients aged over 80 years, patients with severe stroke, or patients with lacunar stroke.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wahlgren N et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369: 275–282

    Article  CAS  Google Scholar 

  2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581–1587

  3. Albers GW et al. (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283: 1145–1150

    Article  CAS  Google Scholar 

  4. Hill MD and Buchan AM (2005) Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172: 1307–1312

    Article  Google Scholar 

  5. Wardlaw JM et al. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD000213. 10.1002/14651858.CD000213

  6. Hacke W et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768–774

    Article  Google Scholar 

  7. Davis SM et al. (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7: 299–309

    Article  Google Scholar 

  8. Hacke W et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317–1329

    Article  CAS  Google Scholar 

  9. Sandercock P et al. (2008) The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 9: 37

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter M Rothwell.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rothwell, P. Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?. Nat Rev Cardiol 6, 164–165 (2009). https://doi.org/10.1038/ncpcardio1447

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1447

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing